Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | DUT | P33316 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 11/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091309 | 0.88 | DUT (0.44) | PTGS1PTGS2APPDUTPDE4A | |
| SCHEMBL16203391 | 0.86 | APP (0.43) | PTGS1PTGS2APPDUTPDE4A | |
| SCHEMBL12094255 | 0.85 | APP (0.43) | PTGS1PTGS2APPDUTPDE4A | |
| SCHEMBL21533928 | 0.84 | DUT (0.41) | PTGS1PTGS2APPDUTPDE4A | |
| Hydrochloric Acid SCHEMBL22723239 | 0.84 | APP (0.42) | PTGS1PTGS2APPDUTPDE4A | |
| Hydrochloric Acid SCHEMBL22723238 | 0.84 | APP (0.42) | PTGS1PTGS2APPDUTPDE4A | |
| SCHEMBL22170165 | 0.82 | DUT (0.48) | PTGS1PTGS2APPDUTPDE4A | |
| SCHEMBL15247548 | 0.82 | DUT (0.48) | PTGS1PTGS2APPDUTPDE4A | |
| SCHEMBL5610531 | 0.82 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DHIF1A | |
| SCHEMBL13091258 | 0.81 | HTR2C (0.39) | DUTPDE4AGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247984-B2 | Uracil containing compounds | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2022-02-15 | — | — | US | disclosed |
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039966-A1 | URACIL CONTAINING COMPOUNDS | UNG, DPYD, DUT | PTGS1 3371/4885PTGS2 3624/4885APP 4016/4885 |
| US-11247984-B2 | Uracil containing compounds | UNG, DPYD, DUT | PTGS1 3371/4885PTGS2 3624/4885APP 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.